Importance The effectiveness of triplet therapy compared with androgen pathway inhibitor
(API) doublets in a heterogeneous patient population with metastatic castration-sensitive …

The advent of more effective treatment combinations for metastatic hormone-sensitive
prostate cancer (mHSPC) has been built on successes in therapy development for …

Background Abiraterone acetate plus prednisolone (herein referred to as abiraterone) or
enzalutamide added at the start of androgen deprivation therapy improves outcomes for …

In the updated analysis of the STAMPEDE phase III trial, 2 years of abirateroneeprednisone
improved both metastases-free survival (MFS)[hazard ratio (HR) 0.54, 95% confidence …

Importance Recently, life-prolonging treatments for patients with advanced prostate cancer
have been introduced in clinical practice. Objective To investigate if the introduction of …

The Oncology Grand Rounds series is designed to place original reports published in the
Journal into clinical context. A case presentation is followed by a description of diagnostic …

Introduction There have been a growing number of treatment options available for men with
metastatic castration-sensitive prostate cancer. Not only have newer agents entered the …

Background and objective The utility of prostate radiotherapy (RT) is unclear in men with
metastatic hormone-sensitive prostate cancer (mHSPC) receiving intensified systemic …

Purpose: Castration-sensitive prostate cancer (CSPC) is a complex and heterogeneous
condition encompassing a range of clinical presentations. As new approaches have …

Opinion Statement Treatment for metastatic hormone–sensitive prostate cancer has
undergone significant evolution in recent years, leading to substantial improvements in …